找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Messenger RNA Therapeutics; Stefan Jurga,Jan Barciszewski Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive licen

[復(fù)制鏈接]
查看: 47179|回復(fù): 63
樓主
發(fā)表于 2025-3-21 17:00:26 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Messenger RNA Therapeutics
編輯Stefan Jurga,Jan Barciszewski
視頻videohttp://file.papertrans.cn/632/631097/631097.mp4
概述Focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics.Discusses the strengths and key challenges of this emerging class of drugs.Provides a state-of-the-art overview
叢書名稱RNA Technologies
圖書封面Titlebook: Messenger RNA Therapeutics;  Stefan Jurga,Jan Barciszewski Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive licen
描述This book focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics and discusses the strengths and key challenges of this emerging class of drugs.?In the past 30 years, extensive research and technological development in many areas have contributed to the emergence of in vitro transcribed mRNA as a therapeutic that has now reached clinical testing. Formulations that protect the mRNA from nucleases and accelerate its cellular uptake, combined with improvements to the mRNA molecules themselves, have been critical advancements for mRNAs to become viable therapeutics. Though once regarded as a serious impediment, the transient nature of mRNA technology is now considered a major advantage in making mRNA therapies safe and, ultimately, a potential game changer in the field of medicine.?.This new book in the .RNA Technologies. series provides a state-of-the-art overview on the emerging field of mRNA therapeutics covering essential strategies for formulation, delivery, and application. It also reviews the promising role in cancer immunotherapy, respiratory diseases, and chronic HBV infection and discusses RNA vaccines in light of the current COVID-19 pandemic
出版日期Book 2022
關(guān)鍵詞mRNA therapeutics; RNA vaccines; SARS-CoV-2; Lipid nanoparticles; Adjuvants; Cancer Immunotherapy; Self-am
版次1
doihttps://doi.org/10.1007/978-3-031-08415-7
isbn_softcover978-3-031-08417-1
isbn_ebook978-3-031-08415-7Series ISSN 2197-9731 Series E-ISSN 2197-9758
issn_series 2197-9731
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Messenger RNA Therapeutics影響因子(影響力)




書目名稱Messenger RNA Therapeutics影響因子(影響力)學(xué)科排名




書目名稱Messenger RNA Therapeutics網(wǎng)絡(luò)公開度




書目名稱Messenger RNA Therapeutics網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Messenger RNA Therapeutics被引頻次




書目名稱Messenger RNA Therapeutics被引頻次學(xué)科排名




書目名稱Messenger RNA Therapeutics年度引用




書目名稱Messenger RNA Therapeutics年度引用學(xué)科排名




書目名稱Messenger RNA Therapeutics讀者反饋




書目名稱Messenger RNA Therapeutics讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:29:37 | 只看該作者
板凳
發(fā)表于 2025-3-22 02:16:56 | 只看該作者
Messenger RNA Therapeutics: Start of a New Era in Medicine,ses of RNA-based therapeutics. Among these, mRNA-based therapy is centered on producing proteins within the cells to supplant deficient or abnormal proteins and in vaccination to a target pathogen. The potential of mRNA therapeutics is evident from the two major mRNA vaccines approved for COVID-19:
地板
發(fā)表于 2025-3-22 08:11:30 | 只看該作者
Hospital-Based RNA Therapeutics,e mRNA is essentially biological software, therapeutic RNA constructs can be rapidly developed. The generation of small batches of clinical-grade mRNA to support IND applications and first-in-man clinical trials, as well as personalized mRNA therapeutics delivered at the point-of-care, is feasible a
5#
發(fā)表于 2025-3-22 08:55:02 | 只看該作者
6#
發(fā)表于 2025-3-22 14:11:04 | 只看該作者
SARS-COV-2 and Other mRNA Vaccines, for the prevention of SARS-COV-2 disease following unprecedented speed of development through to emergency use licensure in around three hundred days from virus sequence availability. Case studies of three SARS-COV-2 mRNA vaccines for which field clinical efficacy data are available are examined an
7#
發(fā)表于 2025-3-22 17:09:04 | 只看該作者
8#
發(fā)表于 2025-3-23 00:37:51 | 只看該作者
Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Ience of HBV-associated liver cancer and cirrhosis. Currently, there is no cure for chronic HBV infection, and novel therapeutic approaches, including gene editing and epigenome engineering, are being investigated. Although promising, the liver-specific delivery, expression and safety profile of thes
9#
發(fā)表于 2025-3-23 04:44:45 | 只看該作者
,Preparation of Synthetic mRNAs—Overview and Considerations,afe. The central advantage of the successful use of synthetic mRNA as a vaccine hinge on being able to rapidly manufacture the mRNA molecules. The synthetic mRNA is prepared in vitro via a cell-free enzymatic process. The aim of this chapter is to provide an overview of the enzymatic mRNA synthesis
10#
發(fā)表于 2025-3-23 06:45:38 | 只看該作者
In Vitro-Transcribed mRNAs as a New Generation of Therapeutics in the Dawn of Twenty-First Century:an efficient delivery system, the host cell ribosomes will be recruited to translate and produce the corresponding desired proteins. Nowadays, about 20?years after the first report as for the use of IVT-mRNA, this technology has all the spotlight on it, due to the recently produced vaccines against
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 17:21
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
玉田县| 石狮市| 方正县| 秦皇岛市| 同德县| 泰州市| 鄂尔多斯市| 武城县| 尖扎县| 三原县| 板桥市| 临邑县| 平乡县| 文昌市| 新巴尔虎左旗| 永顺县| 阿尔山市| 西和县| 茶陵县| 大石桥市| 互助| 澄迈县| 军事| 通许县| 青河县| 万年县| 东方市| 秦安县| 临海市| 东源县| 万盛区| 赤城县| 兰西县| 汉寿县| 民乐县| 陇南市| 个旧市| 伊通| 汶川县| 沾益县| 正安县|